Influence of a New Prophylactic Antibiotic Therapy on the Incidence of Liver Abscesses after Chemoembolization Treatment of Liver Tumors

Geschwind, Jean François H.; Kaushik, Shaifali; Ramsey, Douglas E.; Choti, Michael A.; Fishman, Elliot K.; Kobeiter, Hicham

doi:10.1016/s1051-0443(07)61959-9

Cited by 120 publications

(60 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, three of four patients with postablative abscess had bilioenteric anastomosis, and this condition has been reported to be a risk factor for infectious complications after loco-regional hepatic tumor treatment such as RF ablation (5,25), microwave ablation (29), and embolization (30)(31)(32)(33). In case of chemoembolization in patients with bilioenteric anastomosis, prophylactic therapies have already been proven to be successful (34).…”

Section: Discussionmentioning

confidence: 70%

Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience

Dollinger¹,

Beyer²,

Haimerl³

et al. 2015

Diagn Interv Radiol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 70%

Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience

Dollinger¹,

Beyer²,

Haimerl³

et al. 2015

Diagn Interv Radiol

View full text Add to dashboard Cite

“…However, the current study included only patients who had undergone prior liver resection, some with bilioenteric bypass. Before November 2002, when Geschwind et al 9 published their series demonstrating prophylaxis with tazobactam sodium/piperacillin sodium to have a lower incidence of hepatic abscess and infection after chemoembolization in patients with bilioenteric reconstruction, we used cephalosporin prophylaxis for all patients. In the current study, approximately 54% of complications (13 of 24 complications) were prolonged fever or bacteremia that occurred in 4 patients, 3 of whom had undergone prior bilioenteric reconstruction.…”

Section: Discussionmentioning

confidence: 99%

“…Tazobactam sodium/piperacillin sodium (Zosyn; Lederle, Radnor, PA) was used for antibiotic prophylaxis in patients with bilioenteric communication (e.g., bypass or sphincterotomy) who were treated after 2002. 9 Postprocedural laboratory values were drawn on postprocedure Days 1 and 2. If a patient developed a fever Ͼ38.5°C with associated leukocytosis, blood cultures were drawn and intravenous antibiotics initiated until the final cultures returned.…”

Section: Postprocedural Monitoringmentioning

confidence: 99%

Particle embolization of recurrent hepatocellular carcinoma after hepatectomy

Covey

Maluccio

Schubert

et al. 2006

Cancer

View full text Add to dashboard Cite

BACKGROUNDComplete surgical resection is the mainstay of treatment for patients with hepatocellular carcinoma (HCC). Unfortunately, most patients ultimately develop disease recurrence and the median survival from the time of recurrence is <1 year. The purpose of the current study was to review the authors' experience using bland hepatic arterial embolization to treat recurrent HCC after definitive surgical resection.METHODSThe authors reviewed their single‐center hepatic embolization database from 1995 through 2004 to identify patients who underwent bland hepatic arterial embolization for disease recurrence. Data analyzed included patient demographics, Okuda stage and Child score, imaging findings, and embolization variables. Recurrence‐free survival (from surgery to disease recurrence) and survival time (from recurrence to last follow‐up) were calculated using the Kaplan‐Meier method.RESULTSThe authors identified 45 patients treated with bland embolization for recurrent HCC after resection. Six patients also underwent ablative therapy after embolization. Of the 45 patients, 42 (93.3%) patients had Okuda Stage 1 disease. The median time to recurrence was 13 months. The median survival after embolization was 46 months, and actuarial survival rates at 1 year, 2 years, and 5 years after recurrence were 86%, 74%, and 47%, respectively, with a median follow‐up of 31 months. Patients who developed disease recurrence with a solitary lesion had a significantly improved survival (P = .03) At the time of last follow‐up, 3 patients (6.6%) were alive with no evidence of viable disease.CONCLUSIONSBland arterial embolization was found to be an effective method of salvage therapy for patients with good liver function with recurrent HCC after prior surgical resection. Patients whose disease recurred with a solitary lesion appear to have a significantly increased survival compared with patients who develop disease recurrence with multiple tumors. A small proportion of patients can be rendered without evidence of viable disease. Cancer 2006. © 2006 American Cancer Society.

show abstract

“…and biliary diseases (9)(10)(11)(12). Therefore, we compared the efficacy of oral LVFX and intravenous CEZ for prophylaxis against infectious complications in patients undergoing transcatheter therapy for hepatocellular carcinoma using a prospective study design.…”

Section: Lighter and Less Of A Burden Is Imposed On Patients Howevermentioning

confidence: 99%

Antibiotic Prophylaxis in Transcatheter Treatment of Hepatocellular Carcinoma: an Open Randomized Prospective Study of Oral Versus Intravenous Administration

et al. 2010

View full text Add to dashboard Cite

show abstract

Influence of a New Prophylactic Antibiotic Therapy on the Incidence of Liver Abscesses after Chemoembolization Treatment of Liver Tumors

Cited by 120 publications

References 12 publications

Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience

Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience

Particle embolization of recurrent hepatocellular carcinoma after hepatectomy

Antibiotic Prophylaxis in Transcatheter Treatment of Hepatocellular Carcinoma: an Open Randomized Prospective Study of Oral Versus Intravenous Administration

Contact Info

Product

Resources

About